NASDAQ:NCEL NLS Pharmaceutics (NCEL) Stock Price, News & Analysis $2.61 -0.08 (-2.97%) As of 01:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC Filings About NLS Pharmaceutics Stock (NASDAQ:NCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$2.57▼$2.7050-Day Range$2.49▼$3.3952-Week Range$1.83▼$5.12Volume3,412 shsAverage Volume47,472 shsMarket Capitalization$15.09 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingHold Company Overview NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research has centered on therapies intended to address significant unmet needs in narcolepsy and related disorders. Its principal development program has been Quilibria, an extended-release formulation of mazindol designed to treat excessive daytime sleepiness associated with narcolepsy and potentially other hypersomnia disorders. NLS Pharmaceutics has evaluated the compound through clinical development programs and has also explored additional applications for central nervous system conditions. The company was founded in Switzerland and has conducted its development activities internationally through clinical research and regulatory programs. Publicly available information about its current operations and leadership is limited, and the company’s development portfolio and corporate status may change as programs advance.AI Generated. May Contain Errors. Read More NLS Pharmaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreNCEL MarketRank™: 2.39782551742 of 5 starsNLS Pharmaceutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 628th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingNLS Pharmaceutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNLS Pharmaceutics has a consensus price target of $23.00, representing about 758.2% upside from its current price of $2.68.Amount of Analyst CoverageNLS Pharmaceutics has only been the subject of 1 research reports in the past 90 days.Read more about NLS Pharmaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.91 News SentimentNLS Pharmaceutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NLS Pharmaceutics this week, compared to 1 article on an average week.Search Interest1 people have searched for NCEL on MarketBeat in the last 30 days. MarketBeat Follows2 people have added NLS Pharmaceutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsNLS Pharmaceutics has minimal institutional ownership at this time.Read more about NLS Pharmaceutics' insider trading history. Receive NCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCEL Stock News HeadlinesNewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to MarketNovember 9, 2026 | globenewswire.comNewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone PaymentsNovember 4, 2026 | globenewswire.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 13 at 1:00 AM | Profits Run (Ad)NewcelX Ltd. treibt IND-vorbereitende Aktivitäten für NCEL-101 nach erfolgreichem Pre-IND-Treffen mit der FDA voranSeptember 30, 2026 | de.marketscreener.comDNewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 DiabetesSeptember 28, 2026 | globenewswire.comDer aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.August 27, 2026 | de.investing.comNewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium PricingJuly 31, 2026 | globenewswire.comNewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory BoardJuly 8, 2026 | globenewswire.comSee More Headlines NCEL Stock Analysis - Frequently Asked Questions How have NCEL shares performed this year? NLS Pharmaceutics' stock was trading at $1.90 at the beginning of 2026. Since then, NCEL shares have increased by 41.1% and is now trading at $2.68. How were NLS Pharmaceutics' earnings last quarter? NLS Pharmaceutics Ltd. (NASDAQ:NCEL) issued its earnings results on Friday, September, 18th. The company reported ($0.48) earnings per share for the quarter. When did NLS Pharmaceutics' stock split? Shares of NLS Pharmaceutics reverse split on the morning of Friday, October 31st 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NLS Pharmaceutics? Shares of NCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NLS Pharmaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Palantir Technologies (PLTR), Tesla (TSLA), Viking Therapeutics (VKTX), Energy Transfer (ET), Aldeyra Therapeutics (ALDX) and Datavault AI (DVLT). Company Calendar Last Earnings9/18/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NCEL's financial health is in the Green zone, according to TradeSmith. NCEL has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NCEL Previous SymbolNASDAQ:NLSP CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/APrice Target and Rating Average Price Target for NLS Pharmaceutics$23.00 High Price Target$23.00 Low Price Target$23.00 Potential Upside/Downside+781.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book1.64Miscellaneous Outstanding Shares5,780,000Free Float4,829,000Market Cap$15.09 million OptionableNot Optionable Beta1.09 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:NCEL) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
